Protein Kinase Inhibitors: all 15,278 studies that test it

Page 46 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Pazopanib Maintenance Phase IITerminatedNCT02207309Phase 2Results posted
• Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin LymphomaCompletedNCT02207062Phase 2Results posted
• Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular LymphomaTerminatedNCT02204982Phase 3Results posted
• Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic TelangiectasiaTerminatedNCT02204371Phase 2Results posted
• A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate CancerTerminatedNCT02203513Phase 2Results posted
• A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast CancerTerminatedNCT02202746Phase 2Results posted
• Study to Evaluate PF-04965842 in Patients With Moderate to Severe PsoriasisTerminatedNCT02201524Phase 2Results posted
• Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaCompletedNCT02201329Phase 1Results posted
• Everolimus for Cancer With TSC1 or TSC2 MutationCompletedNCT02201212Phase 2Results posted
• Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid TumorsCompletedNCT02197572Phase 1Results posted
• Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLCCompletedNCT02197247Phase 1Results posted
• Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLCCompletedNCT02197234Phase 1Results posted
• Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD MutationCompletedNCT02196857Phase 2Results posted
• Study of Fruquintinib in Patients With Metastatic Colorectal CancerCompletedNCT02196688Phase 2Results posted
• Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck CancerTerminatedNCT02196168Phase 2Results posted
• Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host DiseaseCompletedNCT02195869Phase 1/2Results posted
• Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver MetastasesCompletedNCT02195011Phase 2Results posted
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by SurgeryCompletedNCT02194829Phase 1/2Results posted
• Pazopanib in Molecularly Selected Patients With Advanced NSCLCTerminatedNCT02193152Phase 2Results posted
• Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)CompletedNCT02191891Phase 1Results posted
• Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy VolunteersCompletedNCT02191865Phase 1Results posted
• Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast CancerCompletedNCT02187991Phase 2Results posted
• LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)CompletedNCT02187783Phase 2Results posted
• An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With MethotrexateCompletedNCT02187055Phase 4Results posted
• Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)TerminatedNCT02186821Phase 2Results posted
• Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade GliomasCompletedNCT02186509Phase 1Results posted
• A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the LungCompletedNCT02185690Phase 1Results posted
• Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by SurgeryCompletedNCT02180867Phase 2/3Results posted
• An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström MacroglobulinemiaActive, not recruitingNCT02180724Phase 2Results posted
• Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin LymphomaActive, not recruitingNCT02180711Phase 1/2Results posted
• Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung CancerCompletedNCT02179671Phase 2Results posted
• A Study of LY2157299 in Participants With Advanced Hepatocellular CarcinomaCompletedNCT02178358Phase 2Results posted
• Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney DiseaseCompletedNCT02177786Phase 2Results posted
• [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to RegorafenibCompletedNCT02175095Not applicableResults posted
• Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing SurgeryTerminatedNCT02169284Phase 2Results posted
• Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic CancerTerminatedNCT02168777Phase 1Results posted
• A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's DiseaseCompletedNCT02167256Phase 2Results posted
• Ibrutinib With Rituximab in Adults With Waldenström's MacroglobulinemiaCompletedNCT02165397Phase 3Results posted
• S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal CancerCompletedNCT02164916Phase 2Results posted
• Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GISTCompletedNCT02164240Phase 1Results posted
• Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung CancerCompletedNCT02163733Phase 1Results posted
• A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal ReceptorsCompletedNCT02162719Phase 2Results posted
• Treatment of Cushing's Disease With R-roscovitineTerminatedNCT02160730Phase 2Results posted
• BGJ398 for Patients With Tumors With FGFR Genetic AlterationsTerminatedNCT02160041Phase 2Results posted
• Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT02159989Phase 1Results posted
• LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF MelanomaCompletedNCT02159066Phase 2Results posted
• A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLLActive, not recruitingNCT02158091Phase 1/2Results posted
• Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)CompletedNCT02157883Phase 1Results posted
• Everolimus for Children With Recurrent or Progressive EpendymomaCompletedNCT02155920Phase 2Results posted
• Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to ErlotinibCompletedNCT02155465Phase 1/2Results posted
• Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast CancerTerminatedNCT02154529Phase 1/2Results posted
• Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid CancerActive, not recruitingNCT02152995Phase 2Results posted
• A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung CancerActive, not recruitingNCT02152631Phase 3Results posted
• Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)CompletedNCT02152007Phase 1Results posted
• A Phase II, Single Arm Study of BGJ398 in Patients With Advanced CholangiocarcinomaTerminatedNCT02150967Phase 2Results posted
• Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)CompletedNCT02149108Phase 3Results posted
• Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung CancerTerminatedNCT02147990Phase 2Results posted
• A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background MethotrexateCompletedNCT02147587Phase 2Results posted
• A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)CompletedNCT02145468Phase 3Results posted
• Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid CancerActive, not recruitingNCT02143726Phase 2Results posted
• Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic LeukemiaActive, not recruitingNCT02143414Phase 2Results posted
• TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid TumorsActive, not recruitingNCT02142803Phase 1Results posted
• Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell LymphomaCompletedNCT02142049Phase 1/2Results posted
• S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast CancerTerminatedNCT02137837Phase 3Results posted
• A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLLCompletedNCT02135133Phase 2Results posted
• A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell CancerCompletedNCT02133742Phase 1Results posted
• Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain MetastasesTerminatedNCT02132598Phase 2Results posted
• LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapyTerminatedNCT02131155Phase 3Results posted
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedNCT02130635Phase 2Results posted
• A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT02130557Phase 3Results posted
• A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)CompletedNCT02130466Phase 1/2Results posted
• Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomasCompletedNCT02129647Phase 2Results posted
• Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaTerminatedNCT02129062Phase 2Results posted
• Palliative Thoracic Radiotherapy Plus BKM120CompletedNCT02128724Phase 1Results posted
• A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)CompletedNCT02127710Phase 2Results posted
• Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571TerminatedNCT02127372Phase 1/2Results posted
• Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 MutationsCompletedNCT02124772Phase 1/2Results posted
• Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential ThrombocythemiaCompletedNCT02124746Phase 2Results posted
• An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-DiseaseTerminatedNCT02123966Phase 2Results posted
• Afatinib in Advanced Refractory Urothelial CancerTerminatedNCT02122172Phase 2Results posted
• Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast CancerCompletedNCT02120469Phase 1Results posted
• A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast CancerTerminatedNCT02120417Phase 2Results posted
• Study of Ruxolitinib in Colorectal Cancer PatientsTerminatedNCT02119676Phase 2Results posted
• A Study of Ruxolitinib in Pancreatic Cancer PatientsTerminatedNCT02119663Phase 3Results posted
• Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung CancerTerminatedNCT02119650Phase 2Results posted
• A Study of LY2835219 in Participants With CancerCompletedNCT02117648Phase 1Results posted
• Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)TerminatedNCT02117479Phase 3Results posted
• An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary ObjectiveCompletedNCT02116803Phase 2/3Results posted
• Single Agent Regorafenib in Refractory Advanced Biliary CancersCompletedNCT02115542Phase 2Results posted
• Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to NilotinibTerminatedNCT02115386Phase 3Results posted
• c-Met Second-Line Hepatocellular CarcinomaCompletedNCT02115373Phase 1/2Results posted
• REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategyCompletedNCT02115113Phase 3Results posted
• Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole AloneTerminatedNCT02115048Phase 2Results posted
• Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and NeckCompletedNCT02113878Phase 1Results posted
• Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) NephropathyCompletedNCT02112838Phase 2Results posted
• Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell LymphomaCompletedNCT02112526Phase 1Results posted
• A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular TumorsTerminatedNCT02110069Phase 2Results posted
• A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid MalignanciesCompletedNCT02108964Phase 1/2Results posted
• Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.TerminatedNCT02108951Phase 3Results posted
• A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast CancerActive, not recruitingNCT02107703Phase 3Results posted

← Protein Kinase Inhibitors overview